For Fc-fused monomeric peptides, Kang et al. from Hanmi Pharm (88) developed a glucagon-like peptide-1 (GLP-1)/glucagon (GCG) dual agonist for the potential treatment of obesity and diabetes by activating both GLP-1 and GCG receptors based on LAPScoveryTM (Long-Acting Protein/Peptide Discovery) technology. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.